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Proteome-wide alterations on 
adipose tissue from obese patients 
as age-, diabetes- and gender-
specific hallmarks
María Gómez-Serrano1,*, Emilio Camafeita2,*, Eva García-Santos1, Juan A. López2, 
Miguel A. Rubio3, Andrés Sánchez-Pernaute4, Antonio Torres4, Jesús Vázquez2 & Belén Peral1,5
Obesity is a main global health issue and an outstanding cause of morbidity and mortality predisposing 
to type 2 diabetes (T2DM) and cardiovascular diseases. Huge research efforts focused on gene 
expression, cellular signalling and metabolism in obesity have improved our understanding of these 
disorders; nevertheless, to bridge the gap between the regulation of gene expression and changes in 
signalling/metabolism, protein levels must be assessed. We have extensively analysed visceral adipose 
tissue from age-, T2DM- and gender-matched obese patients using high-throughput proteomics and 
systems biology methods to identify new biomarkers for the onset of T2DM in obesity, as well as to gain 
insight into the influence of aging and gender in these disorders. About 250 proteins showed significant 
abundance differences in the age, T2DM and gender comparisons. In diabetic patients, remarkable 
gender-specific hallmarks were discovered regarding redox status, immune response and adipose tissue 
accumulation. Both aging and T2DM processes were associated with mitochondrial remodelling, albeit 
through well-differentiated proteome changes. Systems biology analysis highlighted mitochondrial 
proteins that could play a key role in the age-dependent pathophysiology of T2DM. Our findings could 
serve as a framework for future research in Translational Medicine directed at improving the quality of 
life of obese patients.
Obesity, which is defined as an enlargement of the body fat due to an imbalance between energy uptake and 
expenditure, has reached epidemic proportions in the last decades and is now established as the most prevalent 
metabolic disease worldwide, affecting not only adults, but also children and adolescents1. White adipose tissue, 
a critical regulator of adiposity, is recognized not only as the main site of energy storage, but also as a complex, 
essential, and highly active metabolic and endocrine organ2. In humans, the adipose tissue is dispersed through-
out the whole body with major intra-abdominal depots around the omentum, intestines, and perirenal areas as 
well as subcutaneous depots in the buttocks, thighs, and abdomen. These two main depots, the subcutaneous 
(SAT) and the visceral adipose tissue (VAT), exhibit differentiated structural, functional and biochemical proper-
ties3. Increased VAT, rather than the amount of SAT, has been found to be a major correlate of a cluster of diabeto-
genic, atherogenic, prothrombotic and proinflammatory metabolic abnormalities. Moreover, VAT accumulation 
has been linked to ectopic fat deposition in other body sites, such as the muscle, the liver and the heart4. Based 
on these evidences, visceral obesity has been established as a serious and complex phenotype largely connected 
with the development of several co-morbidities such as hypertension, dyslipidaemia, type 2 diabetes (T2DM) and 
cardiovascular diseases (CVD)5. Since T2DM emerges frequently in obese patients, its incidence is also increasing 
at an alarming rate worldwide6. The clinical characteristics of T2DM are usually shown several years after the 
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onset of insulin resistance (IR), where the individual is usually asymptomatic7. Thus, early detection of T2DM, or 
preferably avoidance of disease onset, would be of tremendous benefit for human health.
Our group has been contributing to unveiling the human adipose tissue proteome for the last 10 years. We have 
previously linked obesity to attenuated VAT metabolism, marked down-regulation of mitochondrial functions 
and noticeable alteration of structural proteins, the latter accounting for the morphological changes observed in 
obese adipocytes8. While transcriptomic studies on human obesity are well-documented9, less attention has been 
paid to the proteome of obese adipose tissue. Nevertheless significant proteomic studies in obesity regarding 
mature adipocytes10,11, including metabolic models integrating transcriptomic and proteomic data12, have been 
addressed. Most of the studies have largely relied on a variety of experimental models of obesity and cultured adi-
pocytes, and most of them have resorted to electrophoretic protein separation, which has very limited proteome 
coverage and results in a poor representation of low-abundant or very hydrophobic proteins as well as those with 
extreme pI and molecular weight13,14. On the other hand, current high-throughput proteomic techniques enable 
reliable detection and quantitation of thousands of proteins in complex proteomes without previous electropho-
retic separation based on in-solution, in-gel or on-filter digestion of whole proteomes followed by peptide analysis 
by liquid chromatography coupled to mass spectrometry (LC-MS)15. In spite of their enormous potential, very 
few proteomic studies on obesity and its co-morbidities have resorted to these innovative approaches.
Here, we compare for the first time VAT from obese subjects to investigate the influence of T2DM in protein 
expression based on a high-throughput proteomics approach encompassing peptide labelling with isobaric tags 
for relative and absolute quantitation (iTRAQ) followed by LC-MS analysis. This multiplexed approach pro-
vides a wide dynamic range and proteome coverage, allowing the simultaneous quantitation of up to eight com-
plex proteomes in the same experiment, which offers an invaluable advantage for the analysis of limited sample 
amounts16. Moreover, we have used a most rigorous statistical model recently developed ad-hoc for the treatment 
of quantitative proteomics data, the weighted spectrum, peptide and protein (WSPP) model17, which has been 
validated in a variety of proteomics experiments18-20. Using these state-of-the art proteomics methods we have 
quantitatively assessed not only the differences in VAT protein composition between diabetic and non-diabetic 
obese patients, but also whether gender accounts for significant dissimilarities in T2DM subjects, as wells as the 
influence of aging in obese adipose tissue. Given that aging is known to be a risk factor for obesity and T2DM21, 
and gender differences in adipose tissue distribution have been largely established22, the evaluation of the impact 
of aging and sexual dimorphism on the obese VAT proteome is of outmost interest.
The detailed depiction of the VAT proteome achieved, actually the most comprehensive to date, has unveiled 
a global down-regulation of mitochondrial proteins related to both T2DM development and aging progression, 
while, interestingly, the corresponding protein profiles in the two comparisons turned out to be essentially dissim-
ilar. While the proteome alterations associated with aging were accounted for mainly by a dysfunctional electron 
transport chain (organelle level), the differences associated with T2DM involved a larger repertoire of mitochon-
drial functions, most likely resembling a decrease in the number of mitochondria (cellular level). Moreover, a 
distinctive gender-specific phenotype was discovered in T2DM patients, showing for the first time that after 
T2DM onset women suffer from a more dysfunctional adipose tissue as compared to men due to increased 
pro-inflammatory state and decreased VAT adipocyte hyperplasia. To gain an integrated comprehensive view 
of the VAT proteome dynamics systems biology analyses based on artificial intelligence and pattern recognition 
techniques23 were also performed, highlighting four mitochondrial proteins, related for the first time with human 
obesity, that could play a key role in the age-dependent pathophysiology of T2DM.
Results
The VAT proteome in obesity. Alterations as a function of age, T2DM and gender. For proteome 
profiling, VAT samples were collected from a subgroup of sixteen obese patients (Body Mass Index, BMI ≥ 40 kg/m2) 
with highly homogenous clinical features selected out of 50 subjects initially enrolled who underwent bariat-
ric surgery. Two main groups were enclosed: patients with T2DM (diabetic obese, n = 8) and patients without 
T2DM or other obesity-associated co-morbidity (non-diabetic obese, n = 8). Each of these groups was split into 
two subgroups based on gender (diabetic women, n = 4; diabetic men, n = 4) and age (non-diabetic women over 
45 years, n = 4; non-diabetic women under 35 years, n = 4) (Fig. 1). Patient clinical aspects are summarized in 
Supplementary Table S1. In view of the increased risk of suffering T2DM with age, together with the sexual 
dimorphism reported in obesity, we have compared age- and gender-matched groups in a single experiment.
At 1% peptide False Discovery Rate (FDR) 14,118 unique peptides corresponding to 2,525 unique proteins 
and codified by 2,329 human genes were identified (Supplementary Table S2A). Analysis of the major Gene 
Ontology Cellular Component terms (GOCCs) from these proteins revealed that the main organelles were rep-
resented, composed essentially by cytoplasmic (22%), plasma membrane (13%), nuclear (13%) and mitochon-
drial proteins (7%), with contribution also from the endoplasmic reticulum (4%) and the Golgi apparatus (2%) 
(Supplementary Fig. S1A). To assess the biological relevance of the proteins identified, enrichment analyses using 
DAVID software24 were performed. The GO Biological Process terms (GOBPs) found significantly enriched in 
the VAT proteome comprised well known adipose tissue functions such as Generation of precursor metabolites and 
energy or Glucose and fatty acid metabolic process, and obesity-related events such as Response to oxidative stress 
or Response to unfolded protein (Supplementary Fig. S1B and Table S2B), in agreement with previous studies on 
human VAT proteome8,25. Major mitochondrial pathways were also enriched.
The quantitative proteomics data in this study were analysed using the WSPP statistical model17. Plasma pro-
teins and epidermal cytokeratins were excluded from the analysis to ensure a normal distribution of the dataset 
(Fig. 2A), which finally contained 12,824 unique peptides corresponding to 2,371 proteins codified by 2,245 
different human genes (Supplementary Table S3). The model defines a standardized variable at the protein level, 
Zq, as the mean-corrected log2 ratio expressed in units of standard deviation. In this study, proteins with |Zq| ≥ 2 
(corresponding to p < 0.05) were considered as differentially abundant proteins (DAPs) in each comparison.
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Figure 1. VAT samples and comparative proteomic studies. Two main groups of patients were considered: 
patients with T2DM (diabetic obese) and patients without T2DM (non-diabetic obese). Four groups (n = 4 
each) were constituted as follows: non-diabetic obese women over 45 years, non-diabetic obese women under 
35 years, diabetic obese women over 45 years and diabetic obese men over 45 years. Proteins were extracted from 
individual VAT samples, pooled in their corresponding group and digested. The peptide pools were tagged with 
iTRAQ labels (indicated with different colours) and mixed. The multiplexing capacity of iTRAQ technology 
allowed three differential expression studies.
Figure 2. Protein abundance changes in VAT from obese patients. (A) Dot-plots of protein mean-corrected 
log2 ratios, X′q, vs. their corresponding statistical weight, Wq, showing normal distribution of data in each 
statistical comparison: age (1), T2DM (2) and gender (3). (B) Area-proportional Venn’s diagram showing the 
number of DAPs in the three statistical comparisons obtained with BioVenn software72. (C) Relative overlapping 
of DAPs among comparisons. (D) Number of total, up- and down-regulated DAPs specific to each comparison. 
For further information regarding protein changes and statistical values see also Supplementary Table S3.
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p value UniProt Protein name Symbol Zq
Age comparison
    Extracellular matrix (GO:0031012) 0.00
P14780 Matrix metalloproteinase-9 MMP9 4.25
Q12805 EGF-containing fibulin-like extracellular matrix protein 1 EFEMP1 3.54
P55268 Laminin subunit beta-2 LAMB2 2.90
P51888 Prolargin PRELP 2.64
P02462 Collagen alpha-1(IV) chain COL4A1 2.45
P12110 Collagen alpha-2(VI) chain COL6A2 2.37
     Chromatin assembly or disassembly (GO:0006333) 0.00
P16401 Histone H1.5 HIST1H1B − 2.16
P62805 Histone H4 HIST1H4A − 2.69
Q02539 Histone H1.1 HIST1H1A − 3.04
    Mitochondrial part (GO:0044429) 0.04
Q8NC60 Nitric oxide-associated protein 1 NOA1 − 2.20
P06241 Tyrosine-protein kinase Fyn FYN − 2.21
P24310 Cytochrome c oxidase subunit 7A1, mitochondrial COX7A1 − 2.22
Q9NS69 Mitochondrial import receptor subunit TOM22 homolog TOMM22 − 2.27
P51970 NADH dehydrogenase [ubiquinone] 1 alpha subcom-plex subunit 8 NDUFA8 − 2.28
P53007 Tricarboxylate transport protein, mitochondrial SLC25A1 − 2.42
T2DM comparison  
    Calcium ion binding (GO:0005509) 0.00
P06702 Protein S100-A9 S100A9 3.61
P07996 Thrombospondin-1 THBS1 3.25
P05109 Protein S100-A8 S100A8 3.05
P55083 Microfibril-associated glycoprotein 4 MFAP4 2.81
P13796 Plastin-2 LCP1 2.06
P06703 Protein S100-A6 S100A6 2.02
    Mitochondrion (GO:0005739) 0.00
P99999 Cytochrome c CYCS − 2.01
O75964 ATP synthase subunit g, mitochondrial ATP5L − 2.02
P50213 Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial IDH3A − 2.04
O75947 ATP synthase subunit d, mitochondrial ATP5H − 2.11
Q5VTU8 ATP synthase subunit epsilon-like protein, mito-chondrial ATP5EP2 − 2.12
O75390 Citrate synthase, mitochondrial CS − 2.27
Q02252 Methylmalonate-semialdehyde dehydrogenase [acyl-ating], mitochondrial ALDH6A1 − 2.27
P05091 Aldehyde dehydrogenase, mitochondrial ALDH2 − 2.29
Q5VT66 Mitochondrial amidoxime-reducing component 1 MARC1 − 2.43
P38117 Electron transfer flavoprotein subunit beta ETFB − 2.44
Gender comparison  
    Inflammatory response (GO:0006954) 0.00
P02763 Alpha-1-acid glycoprotein 1 ORM1 5.44
P04003 C4b-binding protein alpha chain C4BPA 3.67
P05155 Plasma protease C1 inhibitor SERPING1 3.15
P10909 Clusterin CLU 2.73
P02751 Fibronectin FN1 2.42
    Oxidation reduction (GO:0055114) 0.01
P49327 Fatty acid synthase FASN 5.59
Q53TN4 Cytochrome b reductase 1 CYBRD1 4.35
P00450 Ceruloplasmin CP 4.21
P07203 Glutathione peroxidase 1 GPX1 2.94
O75891 Cytosolic 10-formyltetrahydrofolate dehydrogenase ALDH1L1 2.69
P22352 Glutathione peroxidase 3 GPX3 2.03
    Oxidation reduction (GO:0055114) 0.00
P40939 Trifunctional enzyme subunit alpha, mitochondrial HADHA − 2.03
Q13162 Peroxiredoxin-4 PRDX4 − 2.73
P00441 Superoxide dismutase [Cu-Zn] SOD1 − 2.81
P00352 Retinal dehydrogenase 1 ALDH1A1 − 3.08
P07195 L-lactate dehydrogenase B chain LDHB − 3.09
P21397 Amine oxidase [flavin-containing] A MAOA − 3.16
P08294 Extracellular superoxide dismutase [Cu-Zn] SOD3 − 3.74
Q92781 11-cis retinol dehydrogenase RDH5 − 6.65
Continued
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A total of 255 DAPs were found when comparing older (mean age 50 years) and younger women (mean 
age 32 years), while 203 proteins showed different abundance between diabetic and non-diabetic women and 
the level of 246 proteins revealed different in women as compared to men. Interestingly, 15–33% of the DAPs 
were common among the three comparisons (Fig. 2B,C). In particular, the T2DM and gender comparisons 
showed the greatest DAPs overlap, 33%, suggesting a high impact of gender on the diabetic phenotype. On the 
other hand, 100–150 DAPs were found to be specific in each comparison (Fig. 2D). These proteins were sep-
arately subjected to category enrichment analyses, where categories with p < 0.05 were considered as signifi-
cantly enriched (Supplementary Tables S4–6). In the age comparison, extracellular matrix related terms were 
found over-represented with up-regulated proteins, whilst translation, transcription and mitochondrion related 
categories were found over-represented with down-regulated proteins (Table 1, Supplementary Table S4). These 
results revealed alterations of translation and transcription processes together with disturbances in the extracel-
lular matrix and the mitochondrion with aging. To validate the pattern of protein abundance changes collagen 
VI (COL6), mitochondrial import receptor subunit TOM22 homolog (TOM22) and histone H4 proteins were 
analysed using Western Blot (WB) and immunohistochemistry (IHC) methods in an independent set of 16 VAT 
samples corresponding to older and younger obese patients. Results showed significant changes consistent with 
the above-described quantitative proteomics results (Fig. 3A,B).
In diabetic compared to non-diabetic patients, the categories found significantly more abundant were Calcium 
binding, Immune response and Inflammation with up-regulated proteins, while categories related to mitochon-
drial structure and function such as Generation of precursor metabolites and energy, ATP synthesis and Pyruvate 
metabolism were over-represented in the group of down-regulated proteins (Table 1, Supplementary Table S5). 
The up-regulation of S100 calcium-binding protein A9, S100A9, and the down-regulation of citrate synthase, 
CS, in diabetic compared to non-diabetic patients were validated by WB in an independent set of 16 diabetic and 
non-diabetic VAT samples (Fig. 3C).
The functional categories revealed differential between women and men add adipose tissue to the broad spec-
trum of physiological differences described between genders. Women showed over-expression of Extracellular 
region and Immune response-related terms, and men comprised up-regulated proteins mainly related to Oxidation 
reduction and Glutathione transferase activity (Table 1, Supplementary Table S6). WB analyses were performed in 
an additional set of 16 obese diabetic women and men for 4 proteins selected from the DAPs pertaining to two 
up-regulated and two down-regulated enriched categories in the gender comparison: fatty acid synthase (FASN), 
glutathione peroxidase 1 (GPX1), amine oxidase [flavin-containing] A (MAOA), and glutathione S-transferase 
Mu 1 (GSTM1). Results confirmed significant changes consistent with the above-described quantitative proteom-
ics results (Fig. 3D).
Impact of age, T2DM and gender on protein function dynamics in obesity. Most proteomic stud-
ies are focused on significant protein changes. This simplification has two serious drawbacks: i) its result strongly 
depends on the arbitrary threshold set for assessing DAPs; and ii) the vast majority of valuable quantitative infor-
mation is overlooked. In contrast, the normal distribution of protein quantifications predicted by the WSPP 
statistical model under the null hypothesis is especially suitable for conducting ontological analyses of complete 
datasets without arbitrary thresholds. Thus, a functional category is considered up- or down-regulated at 5% FDR 
when the changes of its protein components fail to follow a normal distribution and show significantly up- or 
down-regulated, respectively (Supplementary Tables S7–9). Given the hierarchical design of functional annota-
tions (i.e. the occurrence of parent and child GO categories), these often share protein components, which require 
clustering analyses based on the frequency of overlapping terms (Fig. 4A–C).
In the age comparison, a total of 62 categories were found regulated which generated eight category clus-
ters (Fig. 4A, Supplementary Table S7). One of the largest clusters comprises categories related with extracel-
lular matrix proteins (Cluster 1), where the majority of protein components were up-regulated in older vs. 
younger women. The other three large clusters including down-regulated proteins are related to translation 
(Cluster 5), mitochondria (Cluster 7) and chromosome organization processes (Cluster 8), in agreement with 
the above-described enrichment analysis. To illustrate the high degree of coordination of protein changes, the 
cumulative frequency distribution of changes, (Zq), was plotted for the least redundant categories in the cluster 
(Fig. 4D). Results indicate that the aforementioned protein function modulation highlighted by the reduced set 
of DAPs is substantiated by proteome-wide functional analysis.
In the T2DM assessment, 64 categories were found altered, leading to five category clusters (Fig. 4B, 
Supplementary Table S8). A cluster composed of up-regulated proteins in the diabetic vs. non-diabetic women 
related to the immune response can be easily recognized (Cluster 1), together with two additional large clusters 
p value UniProt Protein name Symbol Zq
     Glutathione transferase activity (GO:0004364) 0.00
P09211 Glutathione S-transferase P GSTP1 − 2.35
P28161 Glutathione S-transferase Mu 2 GSTM2 − 2.55
P30711 Glutathione S-transferase theta-1 GSTT1 − 3.49
P09488 Glutathione S-transferase Mu 1 GSTM1 − 5.63
Table 1. Representative enriched categories with some of their DAP components. Functional categories 
were retrieved from the DAVID database. The p value for each term is shown. Relative abundance change of 
proteins is indicated with the corresponding Zq value for each comparison. These values can also be found in 
the extended Supplementary Table S3, where a colour scale in red and blue colours is represented for up- and 
down-regulated proteins, respectively.
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including down-regulated proteins related to mitochondria (Cluster 2) and extracellular matrix (Cluster 3). In 
agreement with the enrichment analyses, the mitochondria cluster comprises not only central energy-related 
categories like Oxidative phosphorylation, but also characteristic mitochondrial metabolic pathways like 
TCA cycle and Valine, leucine and isoleucine degradation. Strikingly, proteome-wide changes related to the adap-
tation of mitochondrial metabolism take place to a similar magnitude in aging and T2DM, as can be observed 
in the relative shift patterns of the mitochondria cluster in Fig. 4D,E, respectively. However, the number of 
down-regulated proteins related to mitochondrial structure and function is higher in the T2DM than in the age 
comparison (Supplementary Tables S7 and S8). Additionally, network analysis of mitochondrial down-regulated 
proteins in the age and T2DM comparisons also revealed a larger repertoire of down-regulated functions in 
T2DM (Supplementary Fig. S2).
The gender comparison yielded 46 regulated categories grouped into eight clusters (Fig. 4C, Supplementary 
Table S9). The largest cluster comprises categories related to immune response (Cluster 2) with up-regulated 
proteins in women compared to men (Fig. 4F). Of note, the up-regulation of proteins involved in steroid hor-
mone biosynthesis (Cluster 8) in men highlight the androgenic phenotype at the adipose tissue level. Altogether, 
enrichment and clustering analyses suggested a gender-dependent plasticity of adipose tissue. In addition, anal-
yses of adipose tissue cellularity in histological sections showed significant changes between women and men 
(Fig. 5). Female adipocytes were significantly larger than those from males as revealed by increased mean-area 
Figure 3. Western blot and immunohistochemistry analyses for DAP validation. (A) IHC detection of 
TOM22 in VAT samples from 4 older and 4 younger non-diabetic patients showing over-expression of TOM22 
staining (in brown) in younger adipose cells, mainly surrounding the nuclei where the mitochondrial are 
located (arrows). Magnification x200 under Nikon Eclipse 90i microscope. a, adipocyte. Scale bars, 50 μ m. 
(B–D) Representative WB analyses of selected DAPs using an additional set of 32 VAT samples (8 per cohort) 
in age, T2DM and gender comparisons. The results were normalized for B-actin density. Underneath, the values 
for relative intensity obtained after densitometry of the bands are means ± SD. Statistical significance was set at 
p < 0.05.
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and mean-equivalent diameter (p < 0.01), confirming cellular hypertrophy in women (Fig. 5A). Meanwhile, the 
fraction of smallest adipocytes (40–60 μ m diameter) was significantly higher in males (Fig. 5B), suggesting a more 
hyperplasic phenotype in men as compared to women (p < 0.05).
Systems biology approach to the prediction of protein function alterations in T2DM 
and aging. A remarkably different pattern of mitochondrial dysfunction has been evidenced in the 
above-described T2DM and age comparisons. To further explore this result, the quantitative proteomics data 
obtained from three cohorts (younger non-diabetic women, older non-diabetic women and older diabetic 
women) were subject to computational modelling based on artificial intelligence and pattern recognition tech-
niques. The Therapeutic Performance Mapping System (TPMS, Anaxomics Biotech.)26–28 was used to generate a 
mathematical model for each cohort based on the DAPs identified in each comparison (Fig. 6A). Each model 
was challenged with a stimulus and a response, providing for each cohort a population of solutions, i.e. sets of 
the protein functional states explaining the network perturbation from the stimulus to the response. In our case, 
the network was stimulated with the functional modulation of the most relevant proteins triggering T2DM while 
the response was set as the disease-causing functional modulation of the whole set of proteins characterized 
as involved in T2DM. The proteins found more functionally affected in one particular direction (activation or 
inhibition) in the model solutions of one cohort compared to the other (older vs. younger and diabetic vs. non 
diabetic) were identified as differentially modulated proteins in that cohort.
TPMS discovered 40 functionally differential proteins (p < 0.05) with altered activation states between the 
models compared, four of which were mitochondrial proteins: proto-oncogene tyrosine-protein kinase Src (SRC), 
SHC-transforming protein 1 (SHC1), TNF receptor-associated factor 3 (TRAF3) in the age assessment; and SRC, 
SHC1 and mitogen-activated protein kinase 10 (MAPK10) in the T2DM comparison (Supplementary Table S10).
Figure 4. Protein function dynamics in obese patients. (A–C) Clustering of the functional categories altered 
in the age (A), T2DM (B) and gender (C) comparisons. A colour scale was used to represent up-regulated 
categories in red and down-regulated in blue. A detailed version of clustered categories is displayed in 
Supplementary Tables S7–9, respectively. (D–F) Alteration of representative cluster categories in the age (D), 
T2DM (E) and gender (F) comparisons. The cumulative frequency of changes (Zq) for the least redundant 
category in each of the clusters highlighted is represented together with a theoretical curve showing a normal 
distribution of data and the experimental curve representing Zq for the whole set of proteins quantified.
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Discussion
Obesity is a highly heterogeneous condition in which body fat distribution, especially VAT accumulation, termed 
visceral obesity, has been found to correlate with metabolic diseases such as T2DM and CVD5. While men have a 
more harmful obese phenotype as compared to women, aging influences fat deposition with significant increase 
in total fat mass, re-distribution of body adipose tissue with enlarged VAT and decline in SAT, as well as ectopic 
fat deposition. Our previous studies have linked obesity to an attenuated metabolism of adipose tissue and a 
marked down-regulation of mitochondrial functions8, while other works have also correlated obesity and related 
co-morbidities with mitochondrial dysfunction of the adipose tissue29,30. Moreover, mitochondrial dysfunction 
has long been considered a major contributor to aging and age-related diseases involving both reactive oxygen 
species (ROS) production and other aspects of mitochondrial physiology such as mitochondrial biogenesis and 
turnover, energy sensing, apoptosis, senescence or calcium dynamics31.
To deepen the knowledge of T2DM development in obesity and the influence of both aging and gender in the 
human adipose tissue, we have resorted to a non-hypothesis-driven strategy that combines a high-throughput 
Figure 5. Evaluation of adipose tissue cellularity based on histological section analyses. Haematoxylin-
eosin stained images from obese diabetic women (n = 4) and obese diabetic men (n = 4) were analysed using 
Adiposoft software. A total of 72 high-resolution images were randomly acquired for the analyses. Minimal 
and maximum threshold for automated measurement of adipocyte diameter was set at 40 μ m and 175 μ m, 
respectively. (A) Normal distribution of mean-area (μ m2) and mean-equivalent diameter (μ m) in diabetic 
women (black series, n = 327) and men (red series, n = 349) adipocytes from a representative experiment.  
(B) % of total adipocytes according to different mean-equivalent diameter ranges (in μ m). Bars represent the 
average of the relative percent of adipocytes in each range ± SD from each group among three independent 
experiments. Statistical significance between diabetic women and men was set at p < 0.05. (C) Representative 
haematoxylin-eosin fields at x40 (left panel) and x100 (right panel) magnification used for adipocyte size 
estimation in both diabetic women and men. Scale bars, 100 μ m.
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proteomics platform, namely iTRAQ labelling and LC-MS, and systems biology tools. Our experimental design 
has allowed not only the extremely robust assessment of protein abundance changes (for which adequate statis-
tics are essential16), but also considerably lower sample amount requirements and LC-MS data acquisition time 
compared to other proteomics methods. To our knowledge, this is the first report that relies on these approaches 
to assess T2DM, aging and gender differences in adipose tissue from obese patients.
In older compared to younger patients, enrichment analysis revealed a significant down-regulation of terms 
related to protein synthesis, chromatin remodelling, mRNA processing, mRNA binding and nucleosome riboso-
mal proteins, while translation and chromosome organization were revealed as two of the most over-represented 
events of down-regulated categories. Changes in chromatin architecture, such as histone modifications32 or global 
heterochromatin loss and redistribution33, have been shown to display characteristic features of aging. Based on pro-
teomic approaches, we have detected the same under-expressed processes in human adipose tissue in relation to aging.
The age-based comparison also unveiled the up-regulation of proteins and categories related to extracellular 
matrix organization, underlining extracellular matrix as the largest cluster of over-represented categories associ-
ated with aging. The adipose tissue is a plastic organ in which extensive remodelling, extracellular matrix expan-
sion and up-regulation of its protein components, as previously reported for COL634, take place in response to 
both aging and obesity, where inappropriately increased and rigid extracellular matrix hinders adipose tissue 
growth35. The steroid hormone biosynthesis cluster was also up-regulated in older compared to younger women 
Figure 6. Systems biology approach to the prediction of protein function alterations in T2DM and aging. 
(A) Computational modelling according to TPMS technology. The DAPs from the iTRAQ-based proteomic 
study were analysed through computational modelling of 3 cohorts: non-diabetic obese women under 35 years, 
non-diabetic obese women over 45 years and diabetic obese women over 45 years. Three mathematical models 
were generated and each of them was challenged with the stimulus (the most relevant proteins triggering 
T2DM) and the response (T2DM effectors). The most probable molecular pathways leading from the stimulus 
to the response through the biological network were traced, revealing the most probable molecular mechanisms 
to develop T2DM in each of the three cohorts. By comparing the mathematical models, a set of functionally 
differential proteins was obtained (p value < 0.05). A detailed description of TPMS technology can be found 
in Supplemental Experimental Procedures. (B,C) Mechanistic predictions related to the onset of T2DM and 
hypothetical interpretation of data. (B) SRC is more activated in both non-diabetic (T2DM comparison) and 
younger women (age comparison). (C) SHC1 inhibition was predicted as over-represented in older  
(age comparison) and diabetic patients (T2DM comparison). Conversely, SHC1 activation was also over-
represented in older non-diabetic women (T2DM comparison). We acknowledged Anaxomics Biotech. for 
panel (A) drawings.
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suggesting a key role for adipose tissue as an extra-gonadal source of steroids over time, in agreement with pre-
vious work36.
Interestingly, down-regulated proteins involved in mitochondrial structure and function have been found 
in aging and T2DM assessments. While the relation between mitochondrial dysfunction and T2DM has been 
extensively reported37,38, its long-suspected association with aging remains to be clarified. As cells and organisms 
age, the efficacy of the respiratory chain tends to diminish, thus increasing electron leakage and reducing ATP 
generation39. Indeed, mitochondrial dysfunction has been described as one of the nine hallmarks of aging40. The 
down-regulation of DAPs related to mitochondrial transport and membrane organization in older vs. younger 
patients illustrates that mitochondrial cellular components and molecular trafficking alterations directly impact 
intra- and inter-organelle crosstalk, and therefore intra- and inter-cellular endocrine communication41. Our 
results also highlight a proteome-wide down-regulation of functional categories related to mitochondrial energy 
metabolism, suggesting a key role for dysfunctional oxidative phosphorylation complexes in older vs. younger 
subjects in agreement with previous studies40. Remarkably, the categories encountered under-represented in dia-
betic vs. non-diabetic patients highlight an adjustment of typical mitochondrial processes such as TCA cycle and 
ATP synthesis coupled to proton transport which were not found in the age-based comparison. To deepen this 
result, CS was found down-regulated in T2DM (Fig. 3C, Table 1), in agreement with previous studies42. Moreover, 
in the T2DM assessment our proteomics study based on human VAT has also unveiled calcium signalling altera-
tions, which have been linked to the development of IR at the mitochondrion and endoplasmic reticulum levels43. 
In particular, S100A9 has revealed significantly over-expressed in diabetic compared to non-diabetic subjects 
(Fig. 3C, Table 1), as earlier reported44.
To our knowledge, this is the first time that a proteome-wide down-regulation of mitochondrial proteins is 
reported in aging and T2DM, as shown in the relative shift patterns of the mitochondria clusters in Fig. 4D,E. 
Of note, the age- and T2DM-based comparisons led to dissimilar categories related to down-regulated mito-
chondrial proteins (Table 1, see also Supplementary Tables S4 and S5) together with dissimilar under-expressed 
categories in the functional and network analyses (Supplementary Fig. S2 and Tables S7 and S8). In aging, 
mitochondrial dysfunction is accompanied by features related to adipose tissue remodelling, such as increased 
extracellular matrix or up-regulation of PPAR signalling mediators. In T2DM, however, a larger repertoire of 
mitochondrial functions has been identified, most likely resembling a reduced number of mitochondria as pre-
viously reported37,45, which also correlates with decreased extracellular components and down-regulated PPAR 
mediators. These differences are likely related to the prodromal vs. pathological state in non-diabetic vs. dia-
betic patients, respectively. Causative inferences for mitochondrial dysfunction are difficult to achieve given the 
cross-sectional design of this study; nevertheless, the mitochondrial alterations caused by aging could reflect 
the early stages of IR development, as this adjustment is also accompanied by other well-recognized changes like the 
extracellular matrix deposition. Longitudinal analyses in non-diabetic patients over time would help clarify these issues.
Well-supported gender differences in adipose tissue distribution and metabolic risk have been found. In men, 
the adipose tissue localizes mainly to the abdominal region, accounting for a larger risk of suffering metabolic dis-
orders46. Women are generally characterized by less VAT and more SAT47, as well as by a lower risk of developing 
obesity-associated co-morbidities. However, female visceral adiposity increases over time, resulting from a shift 
towards a central body fat distribution that increases the risk of T2DM compared to men48. Although some evi-
dences have suggested that variation between men and women would be predominantly sex hormone-dependent, 
other features such as immune response dissimilarities, genes located on sex chromosomes, or specific gender 
conducts could contribute to these differences49.
Proteomic analyses addressing gender differences in adipose tissue are scarce. To our knowledge, this is the 
first proteomic study in which gender differences are reported in VAT from T2DM patients. The large DAP 
overlapping (33%) found between T2DM and gender comparisons suggests a key role for gender in the diabetic 
phenotype. Thus, immune response up-regulated function is over-represented in both the T2DM and the gender 
comparisons (Fig. 4B,C). Despite that increased immune response and a pro-inflammatory state are associated 
with T2DM our results suggest a specific role for immune response in women.
Protein abundance changes also revealed a distinctive male and female phenotype regarding antioxidant 
response (Table 1). Thus, SOD1, SOD3 and several GST proteins were found up-regulated in men, whereas 
ROS-scavenging GPX1 and GPX3 were up-regulated in women. The differential expression of several proteins 
corresponding to Oxidation reduction and Glutathione transferase activity categories between women and men 
were revealed by the above-described proteomic procedures and validated by an orthogonal method (Fig. 3D). 
As far as we know, this is the first time that a gender-specific antioxidant protein pattern is described in T2DM 
patients. On the other hand, results indicate that once T2DM has been established, no gender differences in the 
mitochondrial proteome can be observed.
The adipose tissue contributes to the circulating sex hormones36. Low levels of testosterone are associated with 
IR in men, while increased androgen levels induce IR and T2DM in women50. This gender specificity is found in 
the polycystic ovary syndrome, where female hyperandrogenism is related to IR and T2DM51. Our results involv-
ing the up-regulation of proteins related to steroid hormone biosynthesis in men (mainly characterized by C1, 
C2 and C3 members of aldo-keto reductase family 1, AKR1), as previously reported52, illustrate the androgenic 
phenotype in VAT, providing novel insights into adipose tissue steroid-converting enzymes. This androgenic phe-
notype was associated with the up-regulation of proteins involving chromatin organization which, in turn, could 
underlie improved adipocyte hyperplasic response in males as compared to females. Noteworthy, our data have 
also shown that FASN is significantly over-expressed in women compared to men (Fig. 3D, Table 1), supporting 
that increased VAT in women correlate with hypertrophic adipocytes. In fact, FASN, involved in lipid biosynthe-
sis, has been long associated to hypertrophic visceral fat accumulation53, strengthening our results. In addition, 
histological analysis highlighted a significant enlargement of adipocyte size (adipocyte hypertrophy, Fig. 5A) in 
women, while men show more numerous and smaller adipocytes (adipocyte hyperplasia, Fig. 5B). Consequently, 
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VAT in diabetic obese women as compared to men encloses a higher number of enlarged adipocytes which would 
exceed their vascular supply, leading to local hypoxia, fibrosis, adipocyte dysfunction, and cell death54.
Taken together, our data suggest a worsening of the obese phenotype in women once T2DM emerges due 
to increased pro-inflammatory state and decreased VAT adipocyte hyperplasia compared to men. Accordingly, 
previous studies have shown that diabetic women have poorer glycaemic control and are less likely to reach the 
goals for HbA1c than men55, despite that females demonstrate better adherence to diabetes care56. As far as we 
know this is the first time that a proteomic study reflects that after T2DM onset women suffer from a more dys-
functional adipose tissue as compared to men of similar age.
Additionally, we have resorted to systems biology approaches to gain insight into VAT functional changes, 
particularly into those related to mitochondrial regulation, revealed in this study as a common hallmark of 
aging and T2DM in obese patients. Four mitochondrial proteins were identified as differentially modulated in 
the age and T2DM assessments (Supplementary Table S10). Our data have shown that SRC is over-activated in 
both non-diabetic and younger women, therefore suggesting that SRC activation might play a key role in the 
age-dependent pathophysiology of T2DM. SRC is a redox sensitive enzyme57 whose activity is influenced by sev-
eral regulators or by-products of oxidative phosphorylation related to the aging process. Accordingly, we hypoth-
esize that with the onset of IR the activation of SRC is increased, since T2DM development requires higher levels 
of SRC activation in younger non-diabetic patients (more insulin sensitive) as compared to older non-diabetic 
ones (less insulin sensitive) (Fig. 6B). Interestingly, these evidences have been confirmed by studies showing that 
SRC activation promotes IR through Jun N-terminal kinase activation58.
Computational modelling showed that both the activated and inhibited functional states of SHC1 were found 
statistically differential among the groups of patients (Supplementary Table S10). Our data suggest that the mod-
ulation pattern of SHC1 with aging and IR onset requires greater loss of SHC1 inhibition together with increased 
SHC1 activation in diabetic compared to non-diabetic patients (Fig. 6C). SHC1 gene encodes three isoforms of 
66, 52 and 46 kDa; while p46Shc and p52Shc isoforms are coupled to growth and survival signals, p66Shc medi-
ates pro-apoptotic responses to oxidative stress59 being considered as a negative determinant of life span due to its 
effects on mTOR/S6K cascade promoting obesity and IR60. Our results suggest that more than one SHC1 isoform 
could be contributing to T2DM with a certain dependence of age. While SHC1 inhibition could be mostly related 
to p66Shc, SHC1 activation could be related to p46Shc isoform, accordingly to previous data based on mouse 
models studies61.
Our results suggest that inhibition of TRAF3, a negative regulator of inflammation62, would lead to the 
development of T2DM in non-diabetic obese patients. In agreement with this observation, TRAF3 has been 
recently suggested to undergo a functional switch toward pro-inflammatory modes in obesity63, hence coupling 
over-nutrition to metabolic inflammation, IR, and metabolic disease. Finally, the inhibition of MAPK10 (also 
named JNK3) in non-diabetic patients could be involved in the development of T2DM. MAPK10 plays a protec-
tive role in insulin-secreting cells against death caused by pro-inflammatory cytokines64. Since chronic inflamma-
tion is a well-recognized feature of obesity-related co-morbidities65, our results suggest that MAPK10 inhibition 
might be related to the impairment of analogous processes in VAT. Further characterization of these four differen-
tially modulated proteins in VAT from a wide range of obese patients (diabetic, non-diabetic, older and younger) 
might contribute to clarify these fundamental issues.
The primary limitation of this study is the reduced number of patients finally enrolled after selecting those 
with highly homogeneous clinical features. It must be noted, however, that owing to the difficulties inherent to 
obtaining patient tissue samples, most clinical proteomics studies are based on relatively small patient cohorts 
(see for example25,66,67). In addition, the detrimental effect of the relatively limited number of samples is lessened 
by the application of a robust proteomic procedure and the validated WSPP statistical model. Unquestionably, our 
conclusions would have been reinforced by the inclusion of other patient groups such as younger obese women 
with T2DM; however, it must be taken into account that obese patients manifest T2DM several years after the 
onset of the IR early signs7. The enrolment of obese men without T2DM would have also strengthened our results; 
nevertheless, while female patients consult for obesity before they develop co-morbidities, male patients delay 
consultation until they experience metabolic and cardiovascular complications68. Likewise, although mitochon-
drial dysfunction has been highlighted as a central event in T2DM and aging, and therefore constituted the main 
focus in our systems biology analysis, proteomics has revealed a wide array of biomarkers with a potential role in 
obesity, T2DM and aging that warrant further investigation.
Our innovative combination of state-of-the art proteomics and systems biology approaches has provided 
much insight into the interplay among obesity, T2DM, aging and gender by revealing a striking proteome-wide 
down-regulation of mitochondrial functionality in both diabetic and older obese individuals, together with a 
well-defined gender-specific phenotype in obesity-related T2DM. These findings can contribute to the identifica-
tion of therapeutic targets aimed at improving the quality of life of obese patients in the near future.
Material and Methods
Ethic statement. The study was conducted according to the recommendations of the Declaration of Helsinki 
and was approved by the Ethics Committees of Hospital Clínico San Carlos (Madrid, Spain). Signed informed 
consent was obtained from all subjects.
Biological samples. VAT samples were collected from a subgroup of 16 obese patients (BMI ≥ 40 kg/m2) 
with highly homogenous clinical features selected out of 50 subjects initially enrolled. All the patients were of 
Caucasian origin and underwent bariatric surgery. The biopsies were obtained after an overnight fast, washed 
three times in PBS, partitioned into pieces, and immediately frozen in liquid nitrogen and stored at − 80 °C until 
protein extraction. The surgeon aimed to obtain the samples at the beginning of the surgery and from the same 
anatomical location (omentum) in all subjects. All patients reported that their body weight had been stable for 
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at least three months before the study. None of the non-diabetic subjects suffered T2DM or other obesity associ-
ated co-morbidity (hypertension, dyslipidemia, obstructive sleep apnea syndrome or CVD), and none of them 
was being treated. Inclusion criterion for the diabetic group was suffering from diabetes for at least two years. 
Diabetes was defined by fasting plasma glucose ≥ 7 mmol/L and HbA1c ≥ 6.5% (47.5 mmol/mol). All diabetic 
subjects were being treated with oral anti-diabetic drugs and in two cases with insulin in order to control the 
co-morbidities. The clinical characteristics of the patients enrolled are described in Supplementary Table S1. 
Exclusion criteria in this study are defined in Supplementary Information.
Preparation of protein extracts and on-filter digestion. Proteins were extracted from VAT (about 
100 mg) in radioimmunoprecipitation assay buffer (RIPA) (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 
1% sodium deoxycholate, 0.1% SDS) using the Sample Grinding Kit (GE Healthcare). Protein concentration was 
measured using Pierce BCA Protein Assay (Thermo Scientific) and Direct Detect (EMD Millipore). A protein pool 
was prepared with proteins from the four patients included in each group. One-hundred μ g of proteins from each 
pool were digested on-filter (FASP, Protein Digestion Kit).
iTRAQ labelling and MCX peptide fractionation. Proteomics procedures are scheduled in 
Supplementary Fig. S3 and fully described in Supplementary Information. The peptide pools were isobarically 
labelled (iTRAQ, Sigma-Aldrich), equally mixed and the peptide mixture was desalted onto Oasis HLB C18 
cartridges (Waters). One-fifth of the tagged peptides were dried-down, and the remaining four-fifths were sepa-
rated into 8 fractions using MCX Oasis cartridges (Waters). The peptide fractions were desalted using MicroSpin 
Colums C18 (The Next Group) and vacuum-dried.
LC-MS analyses and protein identification. High-resolution analysis of iTRAQ-labeled pep-
tides was carried out on an Easy nLC 1000 nano-HPLC apparatus (Thermo Scientific) coupled to a hybrid 
quadrupole-orbitrap mass spectrometer (Q Exactive, Thermo Scientific). A total of 7 MS data sets, 1 from the 
unfractionated material and 6 from the corresponding MCX fractions, were registered with 28 h total acquisition 
time. For peptide identification the MS/MS spectra were searched with the SEQUEST algorithm implemented in 
Proteome Discoverer 1.4.0.29 (Thermo Scientific).
Statistical analyses. Descriptive results of continuous variables are expressed as mean ± standard devi-
ation (SD). Statistical analyses were performed using the Statistical Package for Social Science software (v. 22, 
SPSS, Inc). One-way ANOVA (using Bonferroni’s post hoc test) was used to compare the anthropometrical and 
clinical data from the patients, and the statistical significance was set at p < 0.05. Peptide and protein abundance 
changes were assessed at 1% peptide FDR using the WSPP model17. This model provides a standardized variable, 
Zq, which is defined as the mean-corrected log2 ratio expressed in units of standard deviation at the protein level. 
The threshold for differential protein abundance was set at |Zq| ≥ 2 (corresponding to p < 0.05). In addition, ca. 
2.3 · 106 functional category terms with relevance to adipose tissue and obesity were retrieved from the DAVID 
database24 and used with the WSPP model to determine statistically significant changes at the protein function 
level as previously described18,19,69.
Immunoblotting. Fat tissue was homogenized in RIPA buffer and protein extracts (10 μ g) were loaded, 
resolved on SDS-PAGE and transferred to Hybond ECL nitrocellulose membranes as described8. Membranes 
were stained with 0.15% Ponceau red to ensure equal loading after transfer, and then blocked with 5% (w/v) 
BSA in TBS buffer with 0.1% Tween 20. The primary antibodies used were 1:2000 rabbit anti-COL6 and 1:10000 
rabbit anti-total H4 (Abcam); 1:2000 mouse anti-FASN (BD Biosciences); 1:500 rabbit anti-TOM22, 1:5000 rab-
bit anti-CS and 1:1000 rabbit anti-GPX1 (Sigma-Aldrich); 1:1000 goat anti-S100A9; 1:2000 rabbit anti-MAOA, 
1:250 rabbit anti-GSTM1 and 1:2000 goat anti-β -actin (Santa Cruz Biotechnology). Blots were incubated with 
the appropriate IgG-HRP-conjugated secondary antibodies. The immunoreactive bands were visualized with 
ECL-plus reagent kit (GE Healthcare). Blots were exposed for different times. Exposures in the linear range of 
signal were selected for densitometric evaluation. Optical densities of the immunoreactive bands were measured 
using Image J analysis software. In addition, infrared labelled secondary antibodies were used: donkey anti-goat 
IRDye 800 IgG (H + L), donkey anti-mouse IRDye 680RD IgG (H + L) and goat anti-rabbit IRDye 680CW IgG 
(H + L) (Li-Cor Biosciences). Here, the bound complex was detected using the Odyssey Infrared Imaging System 
(Li-Cor Biosciences). The images were analyzed using the Odyssey Application Software to obtain the integrated 
intensities. Statistical comparisons of the densitometry data were made with the independent t-test. Statistical 
significance was set at p < 0.05.
Immunohistochemistry. Five-micron sections of formalin-fixed paraffin-embedded VAT were deparaffin-
ized and rehydrated prior to antigen unmasking. Sections were blocked in normal serum and incubated over-
night with 1:200 rabbit anti-TOM22 (Sigma-Aldrich). Secondary antibody staining was performed using the 
VECTASTAIN ABC kit and detected with diaminobenzidine (DAB) (both from Vector Laboratories). Sections 
were counterstained with haematoxylin prior to dehydration and cover-slip placement, and examined under a 
Nikon Eclipse 90i microscope. As a negative control, the procedure was performed in the absence of primary 
antibody.
Analyses of histological sections for adipose tissue cellularity evaluation. Five-micron sections 
were stained with haematoxylin-eosin under conventional procedures. Histological sections were imaged at 
x40 and x100 magnification with a Nikon Eclipse 90i microscope in an automated fashion and analyzed using 
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Adiposoft software70. Statistical comparisons between groups were made using independent t-test. Statistical sig-
nificance was set at p < 0.05.
Therapeutic Performance Mapping System (TPMS) analyses. Mathematical models that sim-
ulate human physiology in silico26,27,71 were generated by TPMS (Anaxomics Biotech.) in a four-step process: 
1) Hand-curated collection of scientific knowledge relating biological processes to their molecular effectors; 
2) Human biological network; 3) Mathematical model generation (including all linkable human proteins, and 
customized to fit the behaviour of different cohorts through introduction of quantitative proteomics results, i.e. 
DAPs); and 4) Extraction of biological conclusions by comparing protein activation states between models (older 
vs. younger and diabetic vs. non-diabetic women). Computational modelling through TPMS is fully described in 
Supplementary Information.
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